Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
about
Testing women with endometrial cancer for lynch syndrome: should we test all?Hereditary and familial colon cancerGenetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relativesEvaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.Controversies in the management of endometrial carcinoma.Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.Family perspectives in lynch syndrome becoming a family at risk, patterns of communication and influence on relations.Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing.Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review.A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas.Hereditary and common familial colorectal cancer: evidence for colorectal screening.Mismatch repair deficiency testing in clinical practice.Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyEpigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
P2860
Q24562824-75358120-E1B6-4DAB-AF85-1D7DF8B14FCDQ28280647-A031129D-7625-4EAE-BE13-48960656D661Q31139897-2E5D78F3-604B-4883-B702-9C46D1048595Q33874719-230CE3DD-0AA3-4807-9575-B6521218FF3EQ33960894-0B6AA764-6E6F-4DE7-AD65-B7BCE0FA11E7Q34017044-7B0446AF-8D9F-43BF-BDDE-DB460F910D35Q34023517-9A94CAEB-7BC7-46A7-98E1-8DD2A8286BE5Q34282821-0FC3F1D4-E6AD-42FC-BFCC-7881FA46365AQ35063442-5558D2BD-9DC7-4EFB-9EFB-32283A3D3549Q35181103-DA26861D-5432-4570-BC1B-EDC5A6350CA1Q35235483-ADB4B547-A08B-472C-9B53-FA8A630B9066Q36930858-30A90B6F-F970-4904-BBE1-D88748A66EE9Q37798758-55C3E9BC-D2B9-43EC-866E-46F68DCEAD27Q37866075-25ABF753-8554-4E8A-A0B6-07D67AEBF502Q38287107-AC3F527D-6702-493F-8DD0-55A27248D767Q38741029-EDFBB1FB-78B8-4DB4-AA42-9E839726E940Q38848447-6D5AB585-BFE1-41E6-B375-735BB55B4FB4Q39668107-DEABE3B1-C37A-4A2A-85B6-380F9BC7365AQ41726020-3C066D8F-4C9F-444A-9BCD-B5AB33A23CDFQ50976223-792A13C8-8EED-48F8-AD31-AB2F17A02368
P2860
Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Prospective evaluation of DNA ...... in primary endometrial cancer.
@en
Prospective evaluation of DNA ...... in primary endometrial cancer.
@nl
type
label
Prospective evaluation of DNA ...... in primary endometrial cancer.
@en
Prospective evaluation of DNA ...... in primary endometrial cancer.
@nl
prefLabel
Prospective evaluation of DNA ...... in primary endometrial cancer.
@en
Prospective evaluation of DNA ...... in primary endometrial cancer.
@nl
P2093
P1433
P1476
Prospective evaluation of DNA ...... in primary endometrial cancer.
@en
P2093
Adrian Suarez
David M O'Malley
Heather Hampel
Iouri Ivanov
Jeffrey M Fowler
Larry J Copeland
Marino E Leon
Wendy L Frankel
P304
P356
10.1016/J.YGYNO.2009.05.026
P407
P577
2009-06-10T00:00:00Z